GH at a glance
Guardant Health, Inc. (GH, SEC CIK 1576280) filed its latest 10-K annual report on February 19, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 16, 2026 and Form 4 insider filings as recently as November 19, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Guardant Health, Inc. (GH) reported revenue of $982.0 million (up 32.9% from FY2024) and a net loss of $416.3 million. Diluted EPS was -$3.32.
- As of September 30, 2026, 35 institutional investment managers tracked by SignalX reported holding Guardant Health, Inc. (GH) shares worth $9.8 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Monroe Terilyn J. on November 18, 2026 of 500 shares at $140.64 per share.
- In the last 90 days, GH insiders reported 0 open-market purchases ($0) and 17 open-market sales ($4.0M) on Form 4, a net sale of $4.0M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $982.0M
- +32.9% vs prior year
- Insiders · 90 days
- 0 buys · 17 sells
- Net −$4.0M
- 13F holders
- 35 funds
- $9.8B · −1 vs prior quarter
- Latest 8-K
- Nov 16, 2026
- Item 2.03 · Item 3.02 · Item 8.01 · Item 1.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business: Precision oncology company providing liquid biopsy and blood-based tests for cancer detection, treatment selection, and monitoring across all disease stages
- New emphasis: Expanded Guardant Reveal test for late-stage therapy response monitoring; Shield test granted FDA Breakthrough Device status for multi-cancer detection
- Strategic shift: Migration of key tests (Guardant360 Liquid, Reveal) to proprietary Smart Platform leveraging multiomic data and AI for enhanced sensitivity and insights
- Quantitative highlight: Global expansion includes launch of Guardant360 CDx testing at Policlinico Gemelli in Italy (Dec 2025) and reimbursement approval in Japan (July 2023)
- Noteworthy fact: Shield blood test is first FDA-approved and Medicare-covered primary colorectal cancer screening blood test, now included in NCCN screening guidelines
Risk Factors
- Medicare reimbursement 10%+ of revenue in 2025, 2024, 2023; risk from CMS regulation changes hindering direct billing
- Geopolitical and economic instability, including wars, terrorism, pandemics, may disrupt business and affect operating results
- Limited laboratory capacity and unautomated processes constrain scaling; facility expansion and equipment procurement delays possible
- Competitor Roche-owned Foundation Medicine, Exact Sciences, and others increasing M&A and development efforts in liquid biopsy and genomic profiling
- Revenue concentration: Top 5 biopharmaceutical customers contributed 11% of total revenue in 2025, risking material financial impact if lost
Management Discussion & Analysis
- Revenue $982.0M in 2025 vs $739.0M in 2024, up $243M or 32.9% YoY
- Net loss improved to $416.3M in 2025 from $436.4M in 2024, margin not explicitly stated
- Best segment: Oncology tests for clinical customers, supported by expanded Medicare coverage and FDA approvals
- Worst segment: Not explicitly stated; overall net losses indicate ongoing high operating expenses
- Cash & equivalents $1.3B as of Dec 31, 2025; capital allocation details on buybacks/dividends not disclosed
- Increased R&D spending on new product innovation and large clinical studies (e.g., Shield post-approval SOLAR study)
- Management outlook highlights focus on international expansion, payer coverage improvements, and reimbursement risks
AI summary of the GH 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Q3 revenue $361.0M, up 36% YoY from $265.2M
- Operating loss $132.8M vs $99.0M YoY, operating margin (36.8%) vs (37.3%)
- Best segment Screening: $67.6M, up 180% YoY; worst growth Biopharma and data: $59.0M, up 8%
- Cash, equivalents and restricted cash $1.1B; nine-month operating cash outflow $147.1M vs $158.4M
- Outlook: additional operating losses expected; liquidity sufficient for more than 12 months, reimbursement variability remains a headwind
Risk Factors
- New cybersecurity risk triggered by unauthorized portal access, with certain patient records potentially accessed
- AI-enabled attacks increasing speed, scale and sophistication of exploitation
- Regulatory exposure from compromised patient data, including investigations, enforcement actions and penalties
- Operational disruption risk across testing, reporting, billing and reimbursement systems
- Third-party service-provider vulnerabilities potentially compromising Guardant information systems
AI summary of the GH 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.03: Creation of a Direct Financial Obligation
- Item 2.03 points investors to Item 1.01 for details on Guardant Health’s newly created financial obligation
- The obligation relates to the company’s indenture and notes, potentially affecting leverage, interest expense and future liquidity
Item 3.02: Unregistered Sales of Equity Securities
- Convertible Notes sold privately under Section 4(a)(2) and Rule 144A, limiting initial availability to institutional investors
- Maximum 3,553,385 common shares issuable upon conversion, creating potential shareholder dilution
Item 8.01: Other Events
- Proposed offering announced November 11, 2026, signaling planned capital raising by Guardant Health
- Offering pricing announced November 12, 2026, with terms in Exhibit 99.2
Item EX-99.2: Item EX-99.2
- $500M 0% convertible notes due May 15, 2032, with potential $50M upsizing option
- Net proceeds approximately $489.3M, rising to $538.3M if fully upsized
Item EX-99.1: Item EX-99.1
- Proposed $500.0M convertible senior notes due May 15, 2032, plus $50.0M overallotment option
- Refinancing strategy: proceeds may repurchase a portion of 0% convertible notes due 2027
Item 1.01: Entry into a Material Definitive Agreement
- $550M 0% convertible notes due 2032, expanding long-term financing without regular cash interest expense
- $501.7M used to repurchase $395.2M of 2027 notes, reducing near-term refinancing risk
Item 2.02: Results of Operations and Financial Condition
- Guardant Health announced financial results for the quarter ended September 30, 2026
- Detailed revenue, earnings, cash flow and guidance information appears in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Q3 revenue $361.0M, up 36%, led by Oncology revenue $231.3M and Screening revenue $67.6M, up 180%
- Test volumes accelerated: Oncology 117,000, up 58%, and Shield 83,000, up 246% year over year
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Retention signal: founders and Co-CEOs Helmy Eltoukhy and AmirAli Talasaz each received 465,413 target PSUs
- 100% performance-based awards tied to relative TSR versus S&P 500 over three-year and five-year periods
AI summaries of GH 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for GH
Don't miss the next GH filing
- Alerts as it files. A push when GH files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut GH, by share count.
- Ask anything. An AI agent that reads every GH filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Monroe Terilyn J. | Sell | Nov 18, 2026 | 500 | $140.64 |
| Monroe Terilyn J. | Sell | Nov 18, 2026 | 1,200 | $141.79 |
| Monroe Terilyn J. | Sell | Nov 18, 2026 | 1,338 | $142.83 |
| Monroe Terilyn J. | Sell | Nov 18, 2026 | 704 | $143.64 |
| Monroe Terilyn J. | Sell | Nov 18, 2026 | 100 | $144.58 |
| Hidalgo Medina Manuel | M | Nov 17, 2026 | 232 | - |
| Hidalgo Medina Manuel | M | Nov 17, 2026 | 232 | - |
| Tariq Musa | Sell | Nov 16, 2026 | 116 | $149.56 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $739.0M | $982.0M |
| Operating Income | - | -$443.6M | -$437.2M |
| Net Income | -$479.4M | -$436.4M | -$416.3M |
| Op. Margin | - | -60.0% | -44.5% |
| Net Margin | - | -59.0% | -42.4% |
| Balance Sheet | |||
| Total Assets | - | $1.5B | $2.0B |
| Equity | $158.7M | -$139.6M | -$99.3M |
| ROE | -302.1% | 312.5% | 419.2% |
| Per Share | |||
| EPS | $-4.28 | $-3.56 | $-3.32 |
| Cash Flow | |||
| Operating CF | - | -$239.9M | -$184.8M |
| CapEx | $20.5M | $35.1M | $48.3M |
Source: XBRL data in Guardant Health, Inc. (GH)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate GH share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 35 | $9.76B |
| Q2 2026 | 36 | $9.27B |
| Q1 2026 | 36 | $6.00B |
| Q4 2025 | 33 | $5.61B |
| Q3 2025 | 32 | $3.21B |
| Q2 2025 | 33 | $2.74B |
| Q1 2025 | 30 | $1.48B |
| Q4 2024 | 23 | $856.5M |
- D.E. Shaw & Co+1.21M (+96%)
- Citadel Advisors LLC+1.14M (+79%)
- BlackRock+379.6K (+5%)
- Dimensional Fund Advisors+265.8K (+152%)
- Bank of America Corp+249.0K (+25%)
- Invesco Ltd−1.46M (-33%)
- Goldman Sachs Group−976.2K (-26%)
- T. Rowe Price Group−786.5K (-12%)
- Two Sigma Investments−655.6K (-18%)
- Millennium Management−504.4K (-31%)
- Marex Group plc+3.3K
- FMR LLC (Fidelity)−5.49M
- Equitable Holdings Inc−1.7K
Source: 13F-HR filings on SEC EDGAR (aggregated from 258 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
GH filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 19, 2026 | - | - | - |
| 4 | Nov 18, 2026 | - | - | - |
| 4 | Nov 17, 2026 | - | - | - |
| 4 | Nov 17, 2026 | - | - | - |
| 8-K | Nov 16, 2026 | - | Analysis | - |
| 4 | Nov 13, 2026 | - | - | - |
| 4 | Nov 13, 2026 | - | - | - |
| 4 | Nov 12, 2026 | - | - | - |
| 8-K | Nov 5, 2026 | - | Analysis | - |
| 10-Q | Nov 5, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 3, 2026 | - | Analysis | - |
| 8-K | Nov 3, 2026 | - | Analysis | - |
| 4 | Oct 22, 2026 | - | - | - |
| 4 | Oct 19, 2026 | - | - | - |
| 4 | Oct 19, 2026 | - | - | - |
| 4 | Oct 15, 2026 | - | - | - |
| 4 | Oct 13, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
Related Health Care companies
- CDNA · CareDx, Inc.Services-Medical Laboratories
- CSTL · CASTLE BIOSCIENCES INCServices-Medical Laboratories
- CELC · Celcuity Inc.Services-Medical Laboratories
- FTRE · Fortrea Holdings Inc.Services-Medical Laboratories
- FLGT · Fulgent Genetics, Inc.Services-Medical Laboratories
- GRAL · GRAIL, Inc.Services-Medical Laboratories
- LH · LabcorpServices-Medical Laboratories
- NTRA · Natera IncServices-Medical Laboratories
GH SEC filings: frequently asked questions
Are GH insiders buying or selling?
In the last 90 days, Guardant Health, Inc. (GH) officers, directors and 10% owners reported no open-market purchases and 17 open-market sales worth $4.0 million by 6 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold GH stock?
As of September 30, 2026, the largest Guardant Health, Inc. (GH) holders among the 13F filers tracked by SignalX were BlackRock ($1.4 billion), Vanguard Capital Management LLC ($1.0 billion), T. Rowe Price Group ($1.0 billion), Vanguard Portfolio Management LLC ($951.6 million), Franklin Resources ($571.8 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was GH's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Guardant Health, Inc. (GH) reported revenue of $982.0 million (up 32.9% from FY2024) and a net loss of $416.3 million. Diluted EPS was -$3.32. The figures come from the XBRL data in the 10-K.
What are the main risks in GH's latest 10-K?
In the 10-K filed February 19, 2026, Guardant Health, Inc. (GH) flagged: Medicare reimbursement 10%+ of revenue in 2025, 2024, 2023; risk from CMS regulation changes hindering direct billing. Geopolitical and economic instability, including wars, terrorism, pandemics, may disrupt business and affect operating results. (AI summary of the Risk Factors section.)
What did GH report in its latest 8-K?
Guardant Health, Inc. (GH) filed an 8-K on November 16, 2026 reporting Item 2.03 (Creation of a Direct Financial Obligation), Item 3.02 (Unregistered Sales of Equity Securities), Item 8.01 (Other Events) and Item 1.01 (Entry into a Material Definitive Agreement). Item 2.03 points investors to Item 1.01 for details on Guardant Health’s newly created financial obligation.
What are the latest GH SEC filings?
Guardant Health, Inc. (GH) filed its latest 10-K annual report on February 19, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 16, 2026 and a Form 4 insider filing on November 19, 2026.
What is GH's SEC CIK number?
Guardant Health, Inc. (GH)'s SEC Central Index Key (CIK) is 1576280. EDGAR lists every GH filing under that number.
Ask anything about GH
The research agent reads GH's filings, financials, insider trades and 13F holders, then answers with sources.